Keppra SJS Lawsuits in California: What You Can Prove

What SJS/TEN from Keppra cases usually come down to

Medication-injury claims commonly rise or fall on two evidence questions:

• Medical causation: whether the drug is capable of causing the injury (general causation) and whether it more likely than not caused your injury (specific causation).
• Damages: whether the harm is well documented (hospital course, complications, ongoing symptoms, costs, and work impact).

SJS/TEN are widely recognized as rare but potentially life-threatening reactions, typically involving blistering and skin detachment and often involving mucous membranes. Clinical descriptions and typical diagnostic features are summarized by sources such as DermNet NZ (SJS/TEN overview) and Mayo Clinic (SJS symptoms/causes).

Step 1: Proving you had SJS or TEN (not just a rash)

A core early hurdle is establishing that the event meets criteria consistent with SJS/TEN rather than a less severe drug eruption. Records that often matter include:

• Hospital records (ED notes, inpatient progress notes, ICU/burn-unit documentation, discharge summary)
• Dermatology consult documentation describing skin findings and body surface area involvement
• Documentation of mucosal involvement where present (eyes, mouth, genital/urinary)
• Skin biopsy and pathology reports when performed (often used to support diagnosis)
• Clinical photographs (facility photos and/or contemporaneous patient photos)
• Ophthalmology records if there were eye symptoms or complications

If the chart uses inconsistent terms (for example, “drug rash” in one note and “SJS” in another), attorneys typically rely on specialist review of the full record to assess what the presentation most consistently supports.

Step 2: Proving Keppra caused the reaction (general and specific causation)

General causation (can Keppra cause serious skin reactions?)

Official prescribing information for Keppra includes warnings about serious dermatologic reactions, including SJS and TEN. For example, see the U.S. National Library of Medicine’s label database at DailyMed (search “Keppra”) and select the product/label applicable to the patient’s exposure period.

Specific causation (did Keppra cause your SJS/TEN?)

Specific causation is often the main dispute. Clinicians and experts commonly evaluate:

• Medication timeline: when Keppra started (or restarted), dose changes, missed doses, and any re-challenge.
• Onset timeline: when symptoms began relative to exposure.
• Competing causes: other recently started medications (including antibiotics, NSAIDs, anticonvulsants), infections, or other medical conditions. SJS/TEN is commonly described as medication-triggered, but infections are also discussed as potential triggers in general medical references (see Mayo Clinic).
• Differential diagnosis: a structured clinical method to evaluate and rule in/out alternative causes based on the record.
• Dechallenge: whether Keppra was stopped and how the condition evolved afterward (with the important caveat that SJS/TEN may progress despite stopping the suspected drug, particularly early in the course—so dechallenge is only one factor).

Because these cases are medically complex, causation opinions frequently require qualified expert testimony grounded in the actual treatment record.

Step 3: Proving damages (the full scope of harm)

Damages in SJS/TEN matters can extend beyond the initial hospitalization. Evidence often includes:

• Medical costs: hospitalization, specialist care (dermatology/ophthalmology), medications, procedures, follow-up care
• Lost income: time missed from work and, where supported, reduced earning capacity
• Non-economic harm: pain, emotional distress, and loss of enjoyment of life (as supported by records and testimony)
• Long-term complications: scarring and pigment changes; chronic dry eye/vision issues; oral/genital complications; and other sequelae described in clinical references (see DermNet NZ)
• Future care: projected follow-up, medications, therapy, assistive needs, or procedures (often supported by treating providers and retained experts)

Practically, well-organized records (medical records plus itemized billing plus employment documentation) can substantially strengthen the damages presentation.

Potential legal theories in California (and what you generally must show)

The viable theory depends on the facts and the defendants. Commonly evaluated frameworks include:

1) Product liability: failure to warn (manufacturer)

In prescription-drug cases, failure-to-warn claims often focus on whether the warning was adequate given what was known or knowable at the relevant time, and whether a different warning would have changed treatment decisions. California recognizes the “learned intermediary” doctrine in this context (warnings are generally directed to prescribing clinicians rather than directly to patients). See Carlin v. Superior Court (1996) 13 Cal.4th 1104.

2) Product liability: design defect (manufacturer)

Design-defect theories for prescription drugs are not one-size-fits-all. In California, strict-liability design-defect claims against prescription-drug manufacturers are generally restricted under California Supreme Court authority when the drug is properly prepared and accompanied by adequate warnings. See Brown v. Superior Court (1988) 44 Cal.3d 1049. Depending on the circumstances, attorneys may still evaluate other potential product-related theories (including warning-focused claims) and fact-specific negligence arguments.

3) Negligence (manufacturer and/or others in the supply chain)

Depending on the evidence, a negligence theory may be investigated (for example, how safety information was evaluated or communicated). The viability of any negligence claim is fact dependent and can be affected by federal/state preemption issues and other defenses.

4) Medical malpractice / professional negligence (prescriber or healthcare provider)

If the record suggests missed early warning signs, delayed escalation of care, inadequate counseling about urgent symptoms, or other departures from the standard of care, a professional-negligence claim may be evaluated. These cases typically require expert testimony on standard of care, breach, and causation.

The evidence that usually matters most

In investigating a suspected Keppra-related SJS/TEN claim, attorneys commonly seek:

• Complete medication history (all prescription and OTC medications and supplements, start/stop dates)
• Pharmacy dispensing records (to confirm exposure and timing)
• Hospital course documentation (including consults and discharge summary)
• Lab testing and infectious workup (to assess alternative triggers)
• Dermatology, pathology, and biopsy records (if applicable)
• Ophthalmology records (if there were eye findings)
• Prior history of drug reactions or relevant conditions
• Documentation of counseling and warnings provided (what the patient was told, and when)

A clear timeline—exposure, symptom onset, clinical milestones, discontinuation, and recovery—often helps experts explain causation in a way that is understandable and defensible.

What defendants often argue (and how proof addresses it)

• “Another drug caused it.” Records and expert analysis typically focus on timing, known risk associations, and a differential diagnosis.
• “It was an infection, not a medication reaction.” The workup, clinical course, and expert review may be used to evaluate infectious versus medication triggers (see Mayo Clinic).
• “The warning was adequate / the prescriber already knew.” Proof may focus on the exact label language at the time, how the risk was presented, and whether different risk information would likely have altered prescribing or counseling (see Carlin).
• “Care met the standard.” In malpractice-focused cases, experts evaluate whether earlier recognition and treatment would likely have changed the course or reduced severity.

Timing: acting promptly without assuming a one-size-fits-all deadline

California claims can be time-sensitive, and the applicable deadline can depend on the theory, the date of injury and discovery, and other factors (including tolling). By statute, many personal-injury actions are subject to a two-year limitations period (see Code of Civil Procedure section 335.1), while many professional-negligence (medical malpractice) actions have their own limitations framework (see Code of Civil Procedure section 340.5). Because these rules can be complicated in application, it is usually prudent to get a prompt case-specific review.

FAQ

Is a “drug rash” the same as SJS/TEN?

No. Many drug eruptions are far less severe than SJS/TEN. In litigation, the diagnosis is usually evaluated using the full hospital record, specialist documentation, and sometimes biopsy/pathology.

How do you prove Keppra (and not something else) caused SJS/TEN?

Proof typically centers on timing, alternative triggers (other drugs or infections), and a medically supported differential diagnosis tied to the actual treatment record.

Can I have both a drug warning claim and a medical malpractice claim?

Depending on the facts, yes. Some cases are evaluated under more than one theory, but each has its own elements and defenses.

How long do I have to file in California?

Deadlines vary by claim type and case-specific facts. Many personal injury cases reference a two-year period (see CCP 335.1), and many medical malpractice cases have a different framework (see CCP 340.5). Get a prompt case-specific review.

Next step: get a case-specific review

If you want help assessing whether the facts support a product-warning claim, a medical-negligence claim, both, or neither, contact our office.

California disclaimer: This article provides general information about potential California legal issues and is not legal or medical advice. Reading it does not create an attorney-client relationship. Deadlines and legal options depend on specific facts; consult a qualified California attorney about your situation.